Land: Sydafrika
Språk: engelska
Källa: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
ASPEN CARVEDILOL 6,25 mg (Tablets) ASPEN CARVEDILOL 12,5 mg (Tablets) ASPEN CARVEDILOL 25 mg (Tablets) SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): ASPEN CARVEDILOL 6,25 mg (Tablets) ASPEN CARVEDILOL 12,5 mg (Tablets) ASPEN CARVEDILOL 25 mg (Tablets) COMPOSITION: Each ASPEN CARVEDILOL 6,25 mg tablet contains 6,25 mg Carvedilol . Each ASPEN CARVEDILOL 12,5 mg tablet contains 12,5 mg Carvedilol. Each ASPEN CARVEDILOL 25 mg tablet contains 25 mg Carvedilol. PHARMACOLOGICAL CLASSIFICATION: A 7.1.3 Other hypotensives. PHARMACOLOGICAL ACTION: Carvedilol is a competitive non-selective beta 1 and 2-adrenergic blocking agent with also alpha-adrenergic blocking activity and no intrinsic sympathomimetic activity. Carvedilol reduces peripheral vascular resistance through vasodilation and suppresses the renin-angiotensin-aldosterone system through beta blockade. Pharmacokinetics: Carvedilol is absorbed from the gastrointestinal tract and extensively metabolised in the liver, primarily by aromatic ring oxidation and glucuronidation. Absolute bioavailability is about 25% due to the considerable first-pass metabolism. Peak plasma concentration occurs approximately 1 hour after administration. Protein binding, especially to albumin, is more than 98%. The absorption rate of carvedilol is slowed by food, but the bioavailability appears not to be affected. The elimination half-life is 6-10 hours and excretion is mainly in the bile, with a small part (about 15%) excreted via the kidneys. The plasma level of carvedilol is an average of about 50% higher in the elderly, compared with younger patients. The plasma level of carvedilol is 5 times higher in patients suffering from cirrhosis of the liver, than in healthy subjects. INDICATIONS: Treatment of mild to moderate essential hypertension. Treatment of Läs hela dokumentet